Oncology

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

Jack Cuzick
Jack Cuzick

JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.

Download this interview

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial">Audio Journal of Cardiovascular Medicine: Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial
  • Audio Journal of Oncology Breast Cancer Special 2005
  • Reporting from: - San Antonio Breast Cancer Symposium, December 8-11, 2004 - European Society for Medical Oncology Congress, October 29-November 10,

  • Audio Journal of Oncology Breast Cancer Special 2005
  • Reporting from: - San Antonio Breast Cancer Symposium, December 8-11, 2004 - European Society for Medical Oncology Congress, October 29-November 10, 2004,

    Post a comment

    Subscribe to Audio Medica Podcast